Ravi Kamepalli, MD
Infectious Disease · Lagrange, GANPI 1669464681
Payments from drug & device makers
Across 314 payments — averaging $169.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$30K
- Novo Nordisk AS$14K
- Astellas Pharma Global Development$4K
- Merck$2K
- Ferring Pharmaceuticals AS$2K
- Kerecis Limited$352
- plus $2K from 33 others
Across 1 payment — averaging $50.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk$50
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 10 | $29,784 |
| Novo Nordisk AS | 214 | $13,640 |
| Astellas Pharma Global Development | 1 | $3,936 |
| Merck | 19 | $2,081 |
| Ferring Pharmaceuticals AS | 1 | $1,700 |
| Kerecis Limited | 7 | $352 |
| Pfizer | 2 | $196 |
| AstraZeneca | 3 | $169 |
| Smith+Nephew | 6 | $143 |
| Astellas Pharma US Inc | 5 | $135 |
| Ascensia Diabetes Care US Inc. | 1 | $112 |
| Reprise Biomedical, Inc. | 9 | $104 |
| Ferring Pharmaceuticals Inc. | 5 | $95 |
| Zealand Pharma US, Inc. | 1 | $65 |
| Abbott | 1 | $52 |
| Melinta Therapeutics, LLC | 2 | $48 |
| Corcept Therapeutics | 2 | $41 |
| Imbed Biosciences Inc. | 1 | $37 |
| Stryker | 1 | $36 |
| EMD Serono, Inc. | 1 | $35 |
| Bone Support Inc. | 1 | $33 |
| Scpharmaceuticals Inc. | 1 | $33 |
| Novo Nordisk | 1 | $32 |
| La Jolla Pharmaceutical Company | 2 | $31 |
| Medtronic | 1 | $27 |
| Paratek Pharmaceuticals, Inc. | 1 | $24 |
| Cvrx, Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $22 |
| Polymedics Innovations Inc. | 1 | $18 |
| Mimedx Group, Inc. | 1 | $18 |
| Aroa Biosurgery Incorporated | 1 | $18 |
| Reddress USA, Inc. | 1 | $18 |
| AbbVie | 1 | $15 |
| Biowound Solutions, Inc. | 3 | $14 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $12 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
| Dexcom, Inc. | 1 | $12 |
| Convatec Inc. | 1 | $11 |
| Lifenet Health | 1 | $6 |
How this compares
$53,139 in reported general payments places this provider in the 80th percentile of 260 infectious disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Lagrange
- Mark MulliganAtlanta$4.6M
- Nadine RouphaelAtlanta$2.4M
- Leila HojatAtlanta$2.2M
- Kimberly WorkowskiAtlanta$2M
- Robin DretlerDecatur$1.8M
- Harold KatnerMacon$1.3M
- Andrew DoldDacula$1.1M
- Jeffrey StephensMacon$1M
- Jose VazquezAugusta$967K
- Cheryl NewmanAugusta$945K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.